LEXX lexariabioscience.com: Koefisien utang jangka dawa marang modal

The dynamics of the current long-term debt-to-equity ratio on the GURU.Markets chart are driven by patent protection for absorption methods, which creates barriers to entry. Lexaria Bioscience relies on B2B sales of its DehydraTECH technology to accelerate substance delivery. A breakthrough in the bioavailability of GLP-1 and CBD drugs is transforming the pipeline, while 0.01 serves as the baseline value for the debt sustainability parameter of Lexaria Bioscience.

A conservative approach to analyzing Lexaria Bioscience requires an assessment of its financing structure's stability. The ratio compares liabilities with a maturity of over one year to net asset value, measuring the degree of financial leverage. The current long-term debt-to-equity ratio stands at 0.01, reflecting the company's reliance on external borrowings. The low leverage level on the chart confirms the safety of the DehydraTECH licensing model. This provides Lexaria Bioscience with significant pricing power without the risk of debt overload.